Join us on 12-15-2022 for a live seminar about RNA SEQ
Join us on 12-15-2022 for a live seminar about RNA SEQ
We envision a future in 20 years where soluble TCR modalities become as common of a treatment paradigm as antibodies are today. Keyway unites innovative minds in antibody discovery with the pioneering minds behind TCR therapeutics, to provide comprehensive, proprietary technology and capabilities for end-to-end discovery of TCR mimics (TCRms) and engineered TCRs.
TCRms are antibodies that have been developed to target peptides presented on the cell surface in the context of major histocompatibility complexes (pMHCs), opening up a wide range of intracellular targets, including novel cancer targets. Keyway‘s robust TCRm discovery services is an end-to-end solution from target idea to final panel of therapeutic leads. We start with high-quality pHLA generation for discovery and optimization and complete campaigns with in vitro and in silico specificity testing to reduce the off-target effects that can limit many TCRm therapeutics in the clinic.
Proprietary protocols, workflows, know-how, technology, and materials for the consistent generation of high-quality pMHC complexes, giving you the high-quality antigens that are crucial for the generation of high-quality therapeutic leads.
Alloy’s full suite of in vivo, in vitro and in silico antibody discovery capabilities are tailored to identifying and optimizing a diverse set of antibodies that bind to a specific pMHC complex. This approach selects for non-specific binders to related pMHC complexes while also using Alloy’s AI/ML workflows to reduce genome-wide polyreactivity.
We leverage pMHC phage and eukaryotic display libraries for specificity testing to address off-target non-specificity effects, to give you greater confidence that Keyway-generated therapeutic candidates are successful as they advance to clinical trials.
Dongxing Zha, PhD, CTO of TCR Discovery & Engineering and CEO of Keyway TCR Discovery
Keyway offers additional TCRm engineering into your preferred output of choice and integrates closely with our Translational Medicine offering for in vivo and in vitro functional testing.
Multiple proprietary T-cell engagers (including CD3 and CD28) and high-throughput bispecific generation and screening.
mRNA- and lentiviral-based vector system producing CAR-Ts and characterization.
Translational Medicine gives early insights into the functional activity of candidates generated from Keyway TCR discovery projects.
Our phage display for soluble TCRs workflow will leverage our proprietary optimized synthetic phage library designed to expand the sequence space beyond natural repertoire, followed by a transgenic humanized mouse in vivo discovery platform optimized for human TCR-based therapeutics.
Learn about our latest product updates, events, and TCR discovery collaborations.
Through our collaboration with leading antisense inventor Sudhir Agrawal, we are offering proprietary compounds that enable RNA-based therapeutics to avoid off-target effects of the past and actively engage the immune system for therapeutic effect. License these for use in your ASO discovery efforts to turn your RNA biology into viable therapeutic formats.
We offer these licenses at preferred terms to spur your innovation efforts
We’ll work together to find you the best therapeutic TCRm to achieve your cancer immunotherapy pipeline goals.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
San Francisco, CA
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.
Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.
G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.
I’d like more material about Keyway TCR Discovery
Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:
1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target
Upon filling out this form, you will receive an email with a link to the webinar recording.
